Skip to main content

Table 2 Nonalcoholic fatty liver disease (NAFLD) activity score in the five groups

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

 

Steatosis

Lobular inflammation

Ballooning

NAS

Control

0

0

0

0

Vehicle

1.3 ± 0.5

2.3 ± 0.5

2

5.7 ± 0.8

Linagliptin 10 mg/Kg

0.8 ± 0.4

2.2 ± 0.4

2

5.0 ± 0.6

Empagliflozin 10 mg/Kg

1

1.3 ± 0.5

1.0 ± 0.6

3.3 ± 0.5

Linagliptin + empagliflozin

0.8 ± 0.4

2

1

3.8 ± 0.4

  1. Data are mean ± SD
  2. NAS nonalcoholic fatty liver disease (NAFLD) activity score
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us